Laurus Labs Limited has addressed recent media reports regarding the temporary freeze of funding under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for 90 days. The company has clarified that this development is unlikely to significantly impact its business operations.
The global antiretroviral (ARV) medicine market stands at approximately $1.5 billion annually, representing only 10% of the total HIV financing budget. Funding for AIDS treatment comes from multiple sources, including country governments, PEPFAR, and the Global Fund. These global agencies have successfully collaborated to control the AIDS pandemic, ensuring medication procurement remains steady even during funding reviews.
Additionally, media reports highlight that the United States has recently decided to rejoin the World Health Organization (WHO), reinforcing its commitment to global health initiatives.
Laurus Labs believes this reinforces stability in global AIDS funding and assures stakeholders there is no immediate need for disclosure under Regulation 30 of the Listing Regulations.
The company remains confident that its operations and business will not face significant disruption due to this temporary funding review.
